Loading...

Therapix Biosciences

DB:4TXA
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4TXA
DB
$14M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The last earnings update was 142 days ago. More info.


Add to Portfolio Compare Print
  • Therapix Biosciences has significant price volatility in the past 3 months.
4TXA Share Price and Events
7 Day Returns
2.8%
DB:4TXA
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-24.3%
DB:4TXA
-7.4%
DE Biotechs
-5.6%
DE Market
4TXA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Therapix Biosciences (4TXA) 2.8% -17.1% -10.8% -24.3% - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 4TXA underperformed the Biotechs industry which returned -7.4% over the past year.
  • 4TXA underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
4TXA
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Therapix Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Therapix Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €2.9.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Therapix Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Therapix Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4TXA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-2.12
NasdaqCM:TRPX Share Price ** NasdaqCM (2019-04-24) in USD $3.4
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Therapix Biosciences.

DB:4TXA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:TRPX Share Price ÷ EPS (both in USD)

= 3.4 ÷ -2.12

-1.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Therapix Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Therapix Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Therapix Biosciences's expected growth come at a high price?
Raw Data
DB:4TXA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Therapix Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Therapix Biosciences's assets?
Raw Data
DB:4TXA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $1.16
NasdaqCM:TRPX Share Price * NasdaqCM (2019-04-24) in USD $3.4
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:4TXA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:TRPX Share Price ÷ Book Value per Share (both in USD)

= 3.4 ÷ 1.16

2.94x

* Primary Listing of Therapix Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Therapix Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Therapix Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Therapix Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Therapix Biosciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Therapix Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Therapix Biosciences expected to grow at an attractive rate?
  • Unable to compare Therapix Biosciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Therapix Biosciences's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Therapix Biosciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:4TXA Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4TXA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4TXA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2018-12-31
DB:4TXA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 -6 -8
2018-06-30 -6 -7
2018-03-31 -6 -8
2017-12-31 -5 -6
2017-09-30 -3 -4
2017-06-30 -3 -3
2017-03-31 -1 -2
2016-12-31 -1 -2
2016-09-30 -2 -2
2016-06-30 -1 -3
2016-03-31 -2 -3
2015-12-31 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Therapix Biosciences is high growth as no earnings estimate data is available.
  • Unable to determine if Therapix Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4TXA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Therapix Biosciences Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4TXA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2018-12-31
DB:4TXA Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -2.12
2018-06-30 -1.56
2018-03-31 -1.75
2017-12-31 -1.79
2017-09-30 -1.72
2017-06-30 -2.20
2017-03-31 -1.92
2016-12-31 -2.13
2016-09-30 -2.39
2016-06-30 -3.53
2016-03-31 -3.80
2015-12-31 -4.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Therapix Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Therapix Biosciences's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Therapix Biosciences's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Therapix Biosciences's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Therapix Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Therapix Biosciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Therapix Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Therapix Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Therapix Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Therapix Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Therapix Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Therapix Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Therapix Biosciences Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4TXA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 -7.71 4.83 3.25
2018-06-30 -7.01 4.57 2.89
2018-03-31 -7.66 4.54 2.70
2017-12-31 -6.24 3.81 1.94
2017-09-30 -4.13 2.58 1.24
2017-06-30 -3.35 1.97 1.02
2017-03-31 -2.10 1.34 0.82
2016-12-31 -1.99 1.29 0.74
2016-09-30 -2.04 2.52 0.69
2016-06-30 -2.78 2.38 0.49
2016-03-31 -2.74 2.49 0.34
2015-12-31 -2.54 1.36 0.24
2015-09-30 -2.55 1.21 0.18
2015-06-30 -1.88 1.38 0.30
2015-03-31 -1.80 1.30 0.35
2014-12-31 -1.85 1.34 0.46
2014-09-30 -2.10 1.49 0.72
2014-06-30 -2.31 1.48 0.99
2014-03-31 0.15 1.24 1.20
2013-12-31 0.06 1.13 1.34
2013-09-30 0.18 0.98 1.05
2013-06-30 -0.01 0.95 -0.77
2013-03-31 -3.05 1.13 -0.44
2012-12-31 -3.55 1.27 2.31
2012-09-30 0.02 -3.12 1.39 -2.37
2012-06-30 0.16 -3.54 1.35 1.34

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Therapix Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Therapix Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Therapix Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Therapix Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Therapix Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Therapix Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Therapix Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Therapix Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Therapix Biosciences has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Therapix Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Therapix Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Therapix Biosciences Company Filings, last reported 6 months ago.

DB:4TXA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 3.61 0.00 2.03
2018-06-30 5.15 0.00 5.10
2018-03-31 6.50 0.00 7.51
2017-12-31 8.39 0.00 9.20
2017-09-30 10.29 0.00 10.74
2017-06-30 11.41 0.00 11.78
2017-03-31 0.57 0.00 0.68
2016-12-31 0.57 0.00 0.68
2016-09-30 0.97 0.00 1.28
2016-06-30 0.33 0.00 0.82
2016-03-31 0.76 0.00 1.28
2015-12-31 1.16 0.00 1.57
2015-09-30 -0.36 0.00 0.02
2015-06-30 -0.07 0.00 0.27
2015-03-31 -0.42 0.00 0.05
2014-12-31 -0.12 0.00 0.16
2014-09-30 0.18 0.00 0.21
2014-06-30 0.84 0.00 1.04
2014-03-31 0.56 0.00 0.80
2013-12-31 1.00 0.00 1.48
2013-09-30 1.02 0.00 1.25
2013-06-30 0.50 0.00 0.73
2013-03-31 -1.47 0.00 1.19
2012-12-31 -1.98 0.00 0.77
2012-09-30 -1.55 0.00 1.22
2012-06-30 -1.19 0.00 1.38
  • Therapix Biosciences has no debt.
  • Therapix Biosciences has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Therapix Biosciences has less than a year of cash runway based on current free cash flow.
  • Therapix Biosciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 61.8% each year.
X
Financial health checks
We assess Therapix Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Therapix Biosciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Therapix Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Therapix Biosciences dividends.
If you bought €2,000 of Therapix Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Therapix Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Therapix Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4TXA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4TXA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Therapix Biosciences has not reported any payouts.
  • Unable to verify if Therapix Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Therapix Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Therapix Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Therapix Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Therapix Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Therapix Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Therapix Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ascher Shmulewitz
COMPENSATION $246,000
AGE 62
TENURE AS CEO 1.4 years
CEO Bio

Dr. Ascher Shmulewitz, M.D., Ph.D. serves as the Chief Executive Officer and served as Interim Chief Executive Officer of Therapix Biosciences Ltd. He has been Chairman of the Board of Therapix Biosciences Ltd. since January 2014. Dr. Shmulewitz has also served as a Board member of Therapix Biosciences Ltd. since February 21, 2013. With doctorate degrees in medicine and engineering, Dr. Shmulewitz spent much of his career as a successful inventor, investor and serial entre­pre­neur in the biomed­ical technolo­gies field, facil­i­tating a wide range of corpo­rate collab­o­ra­tions. He founded and invested in over twenty-four life science compa­nies – many of which enjoyed successful exits via merger & acqui­si­tion trans­ac­tions with large medical device compa­nies – including Arteria Corp., Circulation Inc., Labcoat Medical Ltd., NeoVision Corp. and X-Cardia Inc. In 1995, Dr. Shmulewitz co-founded San Francisco Science and the Incumed Group which both provide seed funding to promising compa­nies. He also founded the private Israeli invest­ment firm and incubator Medgenesis Partners Ltd. which has invested in over a dozen ventures. Between 1988 and 1992, Dr. Shmulewitz held senior executive positions at Advanced Technology Laboratories Inc. He served as Director of Emerald Medical Applications Corp. from December 25, 2016 to January 18, 2018. He received his M.D. from The Technion Medical School and a Ph.D. in Engineering from Tel Aviv University, Israel.

CEO Compensation
  • Ascher's compensation has increased whilst company is loss making.
  • Ascher's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Therapix Biosciences management team in years:

1.4
Average Tenure
50
Average Age
  • The average tenure for the Therapix Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Ascher Shmulewitz

TITLE
Chairman of the Board & Interim CEO
COMPENSATION
$246K
AGE
62
TENURE
1.4 yrs

Adi Zuloff-Shani

TITLE
Chief Technology Officer
COMPENSATION
$192K
AGE
50
TENURE
3.2 yrs

Oz Adler

TITLE
Chief Financial Officer
AGE
31
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Therapix Biosciences board of directors in years:

2.8
Average Tenure
63
Average Age
  • The average tenure for the Therapix Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ascher Shmulewitz

TITLE
Chairman of the Board & Interim CEO
COMPENSATION
$246K
AGE
62
TENURE
5.3 yrs

Zohar Heiblum

TITLE
Independent Director
AGE
63
TENURE
5.7 yrs

Amit Berger

TITLE
Independent Director
AGE
54
TENURE
4.7 yrs

Yafit Stark

TITLE
Independent Director
AGE
64
TENURE
3.8 yrs

Raphael Mechoulam

TITLE
Member of Scientific Advisory Board

James Leckman

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs

Kirsten Müller-Vahl

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs

Michael Davidson

TITLE
Member of Scientific Advisory Board
AGE
68
TENURE
2.8 yrs

Avi Weizman

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs

Michael Bloch

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Therapix Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Therapix Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid-based product for sleep disorders. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.

Details
Name: Therapix Biosciences Ltd.
4TXA
Exchange: DB
Founded: 2004
$12,604,739
4,149,162
Website: http://
Address: Therapix Biosciences Ltd.
Hashahar Tower,
16th Floor,
Givatayim,
5320047,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM TRPX SPON ADR EACH REP 40 ORD (POST SPLIT) Nasdaq Capital Market US USD 25. Sep 2014
DB 4TXA SPON ADR EACH REP 40 ORD (POST SPLIT) Deutsche Boerse AG DE EUR 25. Sep 2014
Number of employees
Current staff
Staff numbers
9
Therapix Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:12
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2018/12/03
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.